Clearpoint Neuro (CLPT) Q4 2024 earnings summary

Executive summary

• Entered a new growth phase called "Fast Forward," focusing on scaling the business and leveraging a robust ecosystem for cell and gene therapy delivery, with a unique platform integrating navigation, predictive modeling, delivery devices, and monitoring software.

• Built a comprehensive infrastructure, including global regulatory clearances, a new manufacturing facility, and an IP portfolio with over 100 patents.

• Expanded biopharma partnerships to over 60, activated more than 100 ClearPoint centers worldwide, and achieved record 25 new global customer activations in 2024.

• Recent FDA approvals for Kebilidi gene therapy (co-labeled with SmartFlow Neuro Cannula) and SmartFlow Cannula for direct brain infusion, with seven clinical-stage partners under expedited FDA review.

• Fast Forward phase aims to extend leadership in cell and gene therapy, evolve product portfolio for efficiency, and expand global installed base.

Financial highlights

• 2024 revenue was $31.4 million, up 31% year-over-year, with a 27% CAGR since 2018.

• Biologics and Drug Delivery revenue grew 27% to $17.3 million; Neurosurgery Navigation revenue rose 21% to $10.3 million; Capital Equipment and Software revenue increased 107% to $3.8 million.

• Gross margin improved to 61% in 2024 from 57% in 2023.

• Operational cash burn decreased 35% to $9.0 million in 2024; cash and equivalents at year-end were $20.1 million.

• Fully repaid all outstanding debt with proceeds from a $16.2 million equity offering.

Outlook and guidance

• 2025 revenue guidance is $36–41 million, representing 15–31% growth, with the range driven by timing of preclinical GLP expansion.

• Targeting operational cash breakeven and 70%+ gross margins by expanding to 150+ global centers.

• Expect 15–20 new global site activations in 2025, building on 25 new activations in 2024.

• Plans to launch new products, expand GLP preclinical services, and pursue additional regulatory approvals.

• Anticipates meaningful revenue from royalty, milestone, and co-development agreements beyond product sales.